Abstract
Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.
Original language | English (US) |
---|---|
Pages (from-to) | S31-S42 |
Journal | Primary care diabetes |
Volume | 4 |
DOIs | |
State | Published - Apr 2010 |
Keywords
- Basal insulin analogue
- Hypoglycemia
- Insulin detemir
- Weight gain
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Nutrition and Dietetics